Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7.

School of Pharmacy, International Medical University, Sesama Center, Plaza, Komanwel, Bukit jalil, 57000 Kuala Lumpur, Malaysia.
Microbiological Research (Impact Factor: 1.94). 02/2007; 162(4):322-7. DOI: 10.1016/j.micres.2006.01.012
Source: PubMed

ABSTRACT In our systematic screening programme for marine actinomycetes, a bioactive Streptomycete was isolated from marine sediment samples of Bay of Bengal, India. The taxonomic studies indicated that the isolate belongs to Streptomyces chibaensis and it was designated as S. chibaensis AUBN1/7. The isolate yielded a cytotoxic compound. It was obtained by solvent extraction followed by the chromatographic purification. Based on the spectral data of the pure compound, it was identified as quinone-related antibiotic, resistoflavine (1). It showed a potent cytotoxic activity against cell lines viz. HMO2 (Gastric adenocarcinoma) and HePG2 (Hepatic carcinoma) in vitro and also exhibited weak antibacterial activities against Gram-positive and Gram-negative bacteria.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Secondary metabolites obtained from Actinomycetales provide a potential source of many novel compounds with antibacterial, antitumour, antifungal, antiviral, antiparasitic and other properties. The majority of these compounds are widely used as medicines for combating multidrug-resistant Gram-positive and Gram-negative bacterial strains. Members of the genus Streptomyces are profile producers of previously-known secondary metabolites. Actinomycetes have been isolated from terrestrial soils, from the rhizospheres of plant roots, and recently from marine sediments. This review demonstrates the diversity of secondary metabolites produced by actinomycete strains with respect to their chemical structure, biological activity and origin. On the basis of this diversity, this review concludes that the discovery of new bioactive compounds will continue to pose a great challenge for scientists.
    Central European Journal of Biology 06/2012; 7(3). · 0.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microbial diversity constitutes an infinite pool of novel chemistry, making up a valuable source for innovative biotechnology. There are over 23,000 known microbial secondary metabolites, 42 % of which are produced by actinobacteria, 42 % by fungi, and 16 % by other bacteria. Actinomycetes are one of the most important groups of secondary metabolite producers. Among various genera, Streptomyces, Saccharopolyspora, Amycolatopsis, Micromonospora and Actinoplanes are the major producers of commercially important biomolecules. The streptomycetes are very potent producers of secondary metabolites. Out of the approximately 10,000 known antibiotics, 45-55 % are produced by streptomycetes. The secondary metabolites produced by actinomycetes have a broad spectrum of biological activities such as antibacterial, antifungal, antiviral, antiparasitic, immunosuppressive, antitumor, insecticidal, antiinflammatory, antioxidant, enzyme inhibitory, diabetogenic and others. Existence of actinomycetes has been reported in the marine habitats. Marine actinomycetes are efficient producers of new secondary metabolites that show a range of biological activities. Bioactive compounds from marine actinomycetes possess distinct chemical structures that may form the basis for synthesis of new drugs. Additional actinomycetes- produced antibiotics could be discovered by subjecting terrestrial and marine samples to innovative enrichments and screening methods. Sequencing actinomycetes genomes may provide insights useful in devising novel agents. This review article highlights the potential activities of actinomycetes.
    Journal of Pharmacy Research. 01/2010; 3(2):250-256.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microbial natural products are the origin of most of the antibiotics in the market today. There is an alarming scarcity of new antibiotics currently under development in the pharmaceutical industry. Still, microbial natural products remain the most promising source of novel antibiotics, although new approaches are required to improve the efficiency of the discovery process. Actinomycetes which are the prolific producers of antibi-otics and important suppliers to the pharmaceutical and other industry they are well known for their ability to produce secondary metabolites many of which are active against pathogenic microorganisms. It is only more recently that actinomycetes have become recognized as a source of novel antibiotics and anticancer agents with unusual structures and properties. They are a promising source of wide range of important enzymes, some of which are produced on an industrial scale, but many other remained to be harnessed. The application of enzymes in diverse biotechnological industries indicates a positive trend which needs to be satisfied with the discovery of novel enzymes and metabolites. Since very few enzymes have been potentially utilize data the industrial level; there is a huge scope for the development of robust and low cost enzymes. Actinomycetes are a reservoir of important enzymes and metabolites due to their versatile genetic repertory. They perform microbial transformations of organic compounds, a field of great commercial value. Members of many genera of actinomycetes have potential for use in the bioconversion of underutilized agricultural and urban wastes into high-value chemical products.
    07/2014; 2(3).

Full-text (2 Sources)

Available from
May 16, 2014